-->

Hyphen Pharma International - SAC Capital 2022-06-06: Receives S$6m Fund Infusion, Digital Assets Valued At S$60m

HYPHENS PHARMA INTL LIMITED (SGX:1J5) | SGinvestors.io HYPHENS PHARMA INTL LIMITED (SGX:1J5)

Hyphen Pharma International - Receives S$6m Fund Infusion, Digital Assets Valued At S$60m

  • Hyphens Pharma (SGX:1J5) received a S$6m fund infusion for a 10% stake in its digital assets under DocMed Technology. The fund will be used to further develop its existing digital infrastructure into an integrated healthtech platform. About 50% of the proceeds will be used to expand into Malaysia, Vietnam and other ASEAN countries.



DocMed Technology

  • DocMed has three verticals:
    • Wholesale of pharmaceuticals and medical supplies in Singapore through Pan-Malayan, a B2B medical hypermart for healthcare professionals, institutions and retail pharmacies. It runs www.pom.com.sg which is a platform for brand principals to provide product information and educational materials to medical professionals;
    • WellAway, a B2C digital platform for doctors to give e-prescriptions and have the prescribed medicines delivered directly to the patients’ homes. WellAway holds the only e-pharmacy licence issued by the Health Science Authority in Singapore; and
    • DocCentral, which offers a suite of tools for medical professionals to collaborate, network, conduct virtual patient visits and coordinate patient care.


Fund injection positive for Hyphens.

  • The fund injection is positive for Hyphens Pharma and 147% for EBITDA, and guided 32% revenue and 28% EBITDA growth for FY23E.


Raised Hyphens Pharma's target price to S$0.46.






Peggy Mak SAC Capital Research | https://www.saccapital.com.sg/ 2022-06-06
SGX Stock Analyst Report BUY MAINTAIN BUY 0.460 UP 0.400



Advertisement



MOST TALKED ABOUT STOCKS / REITS OF THE WEEK



loading.......



ANALYSTS SAY


loading.......